BioPharmSignal logoBioPharmSignal

Biotech News

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

MiMedx (MDXG)MiMedxEarnings

MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, April 29, 2026.

Related news

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MDXGMiMedx2026-02-17 13:00 EST

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

PHARPharming Group2026-07-30 05:00 EST

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

PHARPharming Group2026-07-16 06:00 EST

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

ENTXEntera Bio2026-05-08 20:05 EST

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

STTKShattuck Labs2026-05-07 10:15 EST

Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

RXRXRecursion2026-04-29 11:59 EST

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

ENTXEntera Bio2025-05-09 20:05 EST

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

STTKShattuck Labs2025-05-01 20:20 EST

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

View all latest news

MiMedx

Placental Tissue Products MIMEDX develops and commercializes placental-tissue products for wound care, burns and surgery. Its processing and product portfolio are designed to provide extracellular-matrix and biologic materials that support healing and tissue repair. Wound-Care Portfolio The company has more than a decade of experience...

Recent company news

MDXGMiMedx2026-09-08 12:00 EST

MIMEDX to Participate in Upcoming Investor Conferences

MDXGMiMedx2026-07-29 20:07 EST

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-07-29 20:01 EST

MIMEDX to Acquire Sanara MedTech

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MDXGMiMedx2026-05-21 12:45 EST

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

Stock data

Close
4.69 USD
Market cap
531.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States